Cancer Drug Ukoniq Withdrawn from Market Over Safety Concerns
June 1, 2022Riabni Gains Indication to Treat Rheumatoid Arthritis
June 6, 2022June 6, 2022 – GSK's Priorix® (measles, mumps, and rubella vaccine, live) has gained FDA approval to provide active immunization for the prevention of measles, mumps, and rubella (MMR) in individuals who are at least 12 months old.
- Recommended dosing is one 0.5mL subcutaneous injection given at 12-15 months of age, followed by a second 0.5mL injection administered at 4-6 years of age.
- If Priorix is not given on this schedule, the patient should receive the first and second doses at least four weeks apart.
- Priorix can also be used to provide a second MMR vaccine dose for patients who have received a different MMR vaccine for their first dose.
- Priorix has launched at wholesale acquisition cost (WAC) of $87.31 per dose.